Burn Pain - Market Insight, Epidemiology and Market Forecast - 2032

DelveInsight's 'Burn Pain - Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the Burn Pain, historical and forecasted epidemiology as well as the Burn Pain market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, Canada, and South Korea.

The Burn Pain market report provides current treatment practices, emerging drugs, market share of individual therapies, and the current and forecasted 6MM, Canada, and South Korea Burn Pain market size from 2019 to 2032. The Report also covers current Burn Pain treatment practice, SWOT analysis, reimbursement, market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

• The United States
• EU4 (Germany, France, Italy, Spain) and the United Kingdom
• Canada
• South Korea

Study Period: 2019-2032

Burn Pain Understanding and Treatment Algorithm

Burn Pain Overview

Burn is a skin injury or other organic tissue injury mainly caused by heat, radiation, radioactivity, electricity, friction, or chemical contact.

In the case of burn pain, damage to peripheral sensory neurons and inflammatory processes initiated by the injury exacerbates an acute response and transform burn pain into a complex symptom comprising multiple components, including ongoing background pain and procedural pain during surgical interventions and dressing changes.

Burn symptoms vary depending on the depth of the skin damage, such as a first-degree burn is a minor burn affecting only the outer layer of the skin (epidermis), causing redness and pain. A second-degree burn affects the epidermis and the second layer of skin (dermis), causing swelling and red, white, or splotchy skin. A third-degree burn reaches the fat layer beneath the skin. Burned areas may be black, brown, or white; the skin may look leathery. Third-degree burns can destroy nerves, causing numbness.

Depending on the severity of the injury, burn injury can result in local and debilitating systemic effects on all other organs and systems distant from the burn area.

Burn injury has physical, socioeconomic, and psychological effects, especially in severe burn injury cases. Its effect is not only on the affected part of the body but also affects the organs and systems of the body. It requires an early and prompt response to reduce the effect of the injury. Besides, it requires an interdisciplinary approach and management to prevent the adverse effect of the injury.

Burn Pain Treatment

While burns are classified according to injury depth, area, and severity, pain does not necessarily correlate with these measures. The individual experience of pain varies widely between patients and throughout the healing process in burn injuries. Because individuals have varying pain thresholds, coping abilities, and even physiologic responses to injury, patients may experience disparate pain levels despite having similar injuries. The most immediate and acute form of burn pain is the inflammatory nociceptive pain attributed to burning injury and tissue trauma. Nociceptive pain is often followed by and potentially exacerbated by procedural pain related to the treatment of burn wounds, be it surgical debridement, grafting, staple application and removal, physical therapy, or dressing changes. As burn wounds begin to heal, neuropathic pain characterized by a throbbing or constant burning sensation potentially adds a layer of discomfort (Griggs et al., 2017).

Opioids remain the mainstay of treatment, especially in the acute phase of burn pain, and are the most efficacious medication in perioperative moderate and severe pain management. Opioids are thought not to have a ceiling effect; thus, they can be escalated to a therapeutic effect unless side effects preclude further dose escalation. Unlike other analgesics, opioids do not lead to renal or hepatic dysfunction, though the choice of agent and dosing should include consideration of the patient's comorbidities.

Methadone has both opioid and nonopioid actions. Nonopioid actions include inhibiting the reuptake of monoamines (e.g., serotonin, norepinephrine) and inhibiting N-methyl-D-aspartate (NMDA) receptor, pharmacologic actions that result in additional analgesia. Activation of the NMDA receptor can produce central sensitization (i.e., lowering central nervous system pain thresholds); blocking this receptor may help mitigate the development of hyperalgesia and tolerance.

Acetaminophen is a well-known analgesic with a mechanism of action that has yet to be defined. Studies suggest that there may be involvement of multiple receptor types, including cannabinoid receptors, and also inhibition of prostaglandin synthesis. Clinical studies in surgical patients show improvement in pain and lowered opioid consumption with acetaminophen use.

Alpha-2 agonists have interesting properties that facilitate their use in the analgesic management of burn patients. Besides stimulating the descending inhibitory pain pathways, they have sedative and antihypertensive effects. Clonidine may be used safely in the analgesic management of child burn victims; in some burn centers, it is routinely prescribed for children and adults. Dexmedetomidine has a shorter duration of action than clonidine, and its action is more selective for alpha-2 receptors. One study reported a positive association between ketamine and dexmedetomidine compared to ketamine alone or combined with midazolam during dressing changes in burn patients (Castro et al., 2013).

Continued in the report…..

Burn Pain Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Incident cases of Burns requiring Treatment, Gender-specific Incident cases of Burns, Etiology-specific Incident cases of Burns, Severity-specific Incident cases of Burns, and Treated Incident cases of Burn requiring Pain Management scenario of Burn Pain in the 6MM, Canada, and South Korea covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, Canada, and South Korea from 2019 to 2032.

Key Findings

• As per DelveInsight analysis, incident cases of burns requiring treatment in the 6MM, Canada, and South Korea were found to be approximately 2,101,481 cases in 2021, which are expected to increase by 2032.
• In 2021, the treated incident cases of burns requiring pain management in Canada and South Korea was found to be approximately 46,294 and 463,859 cases, which is expected to change for the study period of 2019-2032.
• According to estimates based on DelveInsight's epidemiology model for Burn Pain, the gender distribution suggests a male predominance across the 6MM, Canada, and South Korea, with approximately 1,149,641 male and 951,840 female cases in the 6MM, Canada, and South Korea in 2021.
• According to estimates based on DelveInsight's epidemiology model for Burn Pain, in the 6MM, Canada, and South Korea, the Etiology Specific Incident Cases of Burns suggest that Flame based etiology specific cases make up the majority of the Burn Pain cases.
• Among the 6MM, Canada, and South Korea, the United States accounted for nearly 26% of the total treated incident cases of burns requiring pain management in the 6MM, Canada, and South Korea in the year 2021 which are expected to increase further by 2032.
• Among EU4 and the United Kingdom, Germany had the highest total treated incident cases of burns requiring pain management with approximately 152,347 cases in 2021, while Italy had the lowest treated incident cases of burns requiring pain management with approximately 81,615 cases in 2021.

Burn Pain Epidemiology

The epidemiology segment also provides the Burn Pain epidemiology data and findings across the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, Canada, and South Korea.

Burn Pain Drug Chapters

The drug chapter segment of the Burn Pain report encloses a detailed analysis of Burn Pain marketed drugs, mid-phase, and late-stage pipeline drugs. It also helps to understand the Burn Pain clinical trial details, expressive pharmacological action, agreements and collaborations, approval, and patent details of each included drug, and the latest news and press releases.

Products detail in the report…

Burn Pain Market Outlook

Burn pain can be intense and long-lasting; its unique nature, changing patterns, and various components make it difficult to control. Burn therapy provides effective and safe pain management, reduces the risk of complications and side effects, preserves the patient's functional capacity (both physical and psychological), and improves the patient's quality of life.

Early severe acute burn pain was treated with strong opioids, local analgesia with local anesthetics, and peripheral-acting drugs. Acute burn pain decreases over time, eliminating the need for injections to administer pain relievers and allowing weaker oral opioids to be identified. The second stage uses a combination of mild oral opioids and peripherally-acting drugs. The final step is pain control with only peripherally acting drugs such as aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs).

A key to successful pharmacological treatment is the concept of multimodal analgesia, which uses dose adjustments to achieve maximal efficacy and reduce the risk of side effects-continuous and accurate assessment of patient pain and response to treatment. Pharmacological treatments do not complement drugs used to control pain in burn patients, and this treatment includes multiple specialties, including psychologists, psychotherapists, physical therapists, and pain specialists (Semara Jaya et al., 2018).

A study by Mendoza et al. (2016) was performed in four burn units in Spain. Burns was classified as severe (90.4%), third-degree (78.2%), and caused by thermal agents (81.8%). Background analgesia consisted of nonopioid drugs (87.5%) and opioids (54.7%) (Morphine [20.3%], morphine and fentanyl [14.1%], or fentanyl monotherapy [15.6%]). Procedural pain was primarily managed with opioid analgesics: fentanyl monotherapy and in combination (84%) and fentanyl monotherapy (48%) administered sublingually (89.1%). The mean patient and healthcare professional satisfaction scores per procedure were 6/10 and 5.5/10, respectively.

Further details in the report…

Key Findings

• The total market size of Burn Pain in the 6MM, Canada, and South Korea combined was USD 249 million in 2021. This is estimated to increase during the forecast period (2022-2032).
• The US consistently held the largest market share among the 6MM, Canada, and South Korea, with USD 140 million in 2021, which is forecast to increase by 2032.
• In 2021, EU4 and the UK countries captured 36% of the total 6MM, Canada and South Korea market.
• Opiod analgesics captured the highest market combining both inpatient and outpatient treatment in the current treatment market, and was estimated to capture market of USD 131 million, in 2021. Treatment by Opiod analgesics is expected to stay constant by 2032.

The United States Market Outlook

This section provides the total Burn Pain market size and market size by therapies in the United States.

EU4 and the United Kingdom Market Outlook

The total Burn Pain market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Canada Market Outlook

The total Burn Pain market size and market size by therapies in Canada are provided.

South Korea Market Outlook

The total Burn Pain market size and market size by therapies in South Korea are provided.

Burn Pain Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the Burn Pain market or expected to get launched in the market during the study period 2019-2032. The analysis covers the Burn Pain market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, and the reasons behind the maximal use of new drugs and allows, the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Burn Pain Development Activities

The report provides insights into different therapeutic candidates in the phase II, and phase III stages and also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers detailed information on collaborations, acquisitions, mergers, licensing, and patent details for Burn Pain emerging therapies.

Reimbursement Scenario in Burn Pain

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

Competitive Intelligence Analysis

We perform competitive and market Intelligence analysis of the Burn Pain market by using various competitive intelligence tools that include-SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

• The report covers a descriptive overview of Burn Pain, explaining its etiology, signs and symptoms, pathophysiology, genetic basis, and currently available therapies.
• Comprehensive insight has been provided into the Burn Pain epidemiology and treatment.
• Additionally, an all-inclusive account of both the current and emerging therapies for Burn Pain is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
• A detailed review of the Burn Pain market; historical and forecasted is included in the report, covering the 6MM, Canada, and South Korea drug outreach.
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the 6MM, Canada, and South Korea Burn Pain market.

Report Highlights:

• The robust pipeline with novel MOA and oral ROA and increasing incidence will positively drive the Burn Pain market.
• The companies and academics are working to assess challenges and seek opportunities that could influence Burn Pain R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• Major players are involved in developing therapies for Burn Pain. The launch of emerging therapies will significantly impact the Burn Pain market.
• Our in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Burn Pain Report Insights

• Patient Population
• Therapeutic Approaches
• Burn Pain Pipeline Analysis
• Burn Pain Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Burn Pain Report Key Strengths

• 11-Years Forecast
• The 6MM, Canada, and South Korea Coverage
• Burn Pain Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

Burn Pain Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• SWOT analysis

Key Questions

Market Insights:

• What was the Burn Pain market share (%) distribution in 2019 and how it would look like in 2032?
• What would be the Burn Pain total market size as well as market size by therapies across the 6MM, Canada, and South Korea during the forecast period (2022-2032)?
• What are the key findings pertaining to the market across the 6MM, Canada, and South Korea and which country will have the largest Burn Pain market size during the forecast period (2022-2032)?
• At what CAGR, the Burn Pain market is expected to grow at the 6MM, Canada, and South Korea level during the forecast period (2022-2032)?
• What would be the Burn Pain market outlook across the 6MM, Canada, and South Korea during the forecast period (2022-2032)?
• What would be the Burn Pain market growth till 2032 and what will be the resultant market size in the year 2032?

Epidemiology Insights:

• What are the disease risk, burdens, and unmet needs of Burn Pain?
• What is the historical Burn Pain patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, Canada, and South Korea?
• What would be the forecasted patient pool of Burn Pain at the 6MM, Canada, and South Korea level?
• What will be the growth opportunities across the 6MM, Canada, and South Korea with respect to the patient population pertaining to Burn Pain?
• Out of the above-mentioned countries, which country would have the highest incident population of Burn Pain during the forecast period (2022-2032)?
• At what CAGR the population is expected to grow across the 6MM, Canada, and South Korea during the forecast period (2022-2032)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

• What are the current options for the treatment of Burn Pain along with the approved therapy?
• What are the current treatment guidelines for the treatment of Burn Pain in the US and Europe?
• What are the Burn Pain marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
• How many companies are developing therapies for the treatment of Burn Pain?
• How many emerging therapies are in the mid-stage and late stages of development for the treatment of Burn Pain?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and licensing activities related to the Burn Pain?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Burn Pain and their status?
• What are the key designations that have been granted for the emerging therapies for Burn Pain?
• What is the 6MM, Canada, and South Korea historical and forecasted market for Burn Pain?

Reasons to buy:

• The report will help in developing business strategies by understanding trends shaping and driving Burn Pain.
• To understand the future market competition in the Burn Pain market.
• Organize sales and marketing efforts by identifying the best opportunities for Burn Pain in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, Canada, and South Korea.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Organize sales and marketing efforts by identifying the best opportunities for the Burn Pain market.
• To understand the future market competition in the Burn Pain market.